^Allschwil, November 20, 2023
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), a biopharmaceutical
Companies with already marketed products and the goal of reaching patients
help those suffering from serious bacterial or fungal infections,
announced today that sales of the antifungal drug continue to be strong
Cresemba® (isavuconazole) through Basilea’s licensing partner Pfizer Inc. (NYSE: PFE,
“Pfizer”) exceeded the threshold in the Asia-Pacific and China region
which will result in an additional sales milestone payment of USD 1.25 million.
was triggered.
David Veitch, Chief Executive Officer of Basilea, said: “This is the third
Milestone payment relating to sales in the Asia-Pacific and China regions
this year. This underlines that Cresemba continues to have a high
medical needs also cover and reflect the significant commercial ones
potential of the product in this region. We are pleased that Cresemba
is well on its way to becoming a world-leading drug for the treatment of
To become patients with invasive mold infections.”
The license agreement between Basilea and Pfizer covers Europe (excluding
Nordic countries), as well as 16 countries in the Asia-Pacific region and China.
Cresemba is approved in 76 countries and is currently marketed in 71 countries,
including the USA, most EU member states and other countries
within and outside Europe. According to the latest available market data
Cresemba’s global in-market sales amounted to
Twelve-month period between July 2022 and June 2023 to USD 421 million
corresponds to growth of 19 percent compared to the same period last year.(1)
About isavuconazole (Cresemba(®))
Isavuconazole is a medicine that can be administered intravenously (IV) and orally
against fungal infections (antimycotic) from the active ingredient class of azoles, which
marketed under the trade name Cresemba(®). Basilea has for isavuconazole
License and sales partnerships for a total of around 115 countries
completed. In the 27 member states of the European Union as well
Great Britain, Iceland, Liechtenstein and Norway isavuconazole is for the
Approved for treatment of adult patients with invasive aspergillosis and
for adult patients with mucormycosis, for whom amphotericin B is not
is appropriate.(2) In China, the oral and the intravenous
Dosage forms for the treatment of adult patients with invasive
Aspergillosis and invasive mucormycosis approved. Isavuconazole is also in the
Approved in the USA and other countries within and outside of Europe,
including Japan.(3)In the USA, Europe and Australia, Cresemba has orphan drug approval
Status for the approved indications.
About Basilea
Basilea is a company founded in 2000 with headquarters in Switzerland
biopharmaceutical company with already marketed products. Our goal
is to discover, develop and market innovative medicines
To help patients suffering from serious bacterial or fungal infections
are sick. With Cresemba and Zevtera we have two successful drugs
brought onto the market for use in hospitals: Cresemba for the treatment of
invasive fungal infections and Zevtera to treat bacterial infections.
We also have a portfolio of preclinical and clinical products
Anti-infective programs. Basilea is listed on the Swiss stock exchange SIX Swiss Exchange
listed (stock exchange symbol SIX: BSLN). Please visit our website basilea.com
(https://www.basilea.com/).
Disclaimer
This communication contains, expressly or implicitly, certain forward-looking statements
Statements such as “believe,” “assume,” “expect,” “predict,” “plan,”
“May”, “could”, “will” or similar expressions regarding Basilea
Pharmaceutica AG, Allschwil and its business activities, including in relation to
the progress, schedule and completion of research and development
as well as clinical studies with product candidates. Such statements include
known and unknown risks and uncertainty factors that result
can that the actual results, the financial situation, the achievements
or achievements of Basilea Pharmaceutica AG, Allschwil significantly from
The information contained in the forward-looking statements may differ
emerge. This notice is dated today. Basilea
Pharmaceutica AG, Allschwil assumes no obligation,
forward-looking statements in the event of new information, future
events or for other reasons.
For further information please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica AG, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Telephone +41 61 606 1102
[email protected] (mailto:[email protected])
Email [email protected] (mailto:[email protected])
This press release is at www.basilea.com
(http://www.basilea.com) available.
Sources
1. IQVIA Analytics Link, June 2023. Information as moving, cumulative «in-
Market» sales of the last twelve months in US dollars.
2. European Public Assessment Report (EPAR) Cresemba: http://www.ema.europa.eu
(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
_Summary_for_the_public/human/002734/WC500196131.pdf) [Zugriff am 19.
November 2023]
3. The approval status and approved indications may vary from country to country
Country may be different.
°